SG11201509428PA - Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b - Google Patents

Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

Info

Publication number
SG11201509428PA
SG11201509428PA SG11201509428PA SG11201509428PA SG11201509428PA SG 11201509428P A SG11201509428P A SG 11201509428PA SG 11201509428P A SG11201509428P A SG 11201509428PA SG 11201509428P A SG11201509428P A SG 11201509428PA SG 11201509428P A SG11201509428P A SG 11201509428PA
Authority
SG
Singapore
Prior art keywords
medicaments
hepatitis
treatment
sulphamoylpyrrolamide
derivatives
Prior art date
Application number
SG11201509428PA
Inventor
Koen Vandyck
Geerwin Yvonne Paul Haché
Stefaan Julien Last
Gowan David Craig Mc
Geert Rombouts
Wim Gaston Verschueren
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of SG11201509428PA publication Critical patent/SG11201509428PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
SG11201509428PA 2013-05-17 2014-05-16 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b SG11201509428PA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP13168291 2013-05-17
EP13175181 2013-07-04
EP13182281 2013-08-29
EP13191209 2013-10-31
EP13198160 2013-12-18
EP14157900 2014-03-05
PCT/EP2014/060102 WO2014184350A1 (en) 2013-05-17 2014-05-16 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

Publications (1)

Publication Number Publication Date
SG11201509428PA true SG11201509428PA (en) 2015-12-30

Family

ID=50884356

Family Applications (4)

Application Number Title Priority Date Filing Date
SG11201509428PA SG11201509428PA (en) 2013-05-17 2014-05-16 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG10201607293UA SG10201607293UA (en) 2013-05-17 2014-05-16 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG10202002604PA SG10202002604PA (en) 2013-05-17 2014-05-16 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG10201607294SA SG10201607294SA (en) 2013-05-17 2014-05-16 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG10201607293UA SG10201607293UA (en) 2013-05-17 2014-05-16 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG10202002604PA SG10202002604PA (en) 2013-05-17 2014-05-16 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG10201607294SA SG10201607294SA (en) 2013-05-17 2014-05-16 Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

Country Status (35)

Country Link
US (3) US9884818B2 (en)
EP (3) EP3594204A1 (en)
JP (3) JP6318238B2 (en)
KR (4) KR101867898B1 (en)
CN (2) CN110003076A (en)
AU (4) AU2014267220B2 (en)
BR (1) BR112015028461A2 (en)
CA (1) CA2909348C (en)
CL (1) CL2015003370A1 (en)
CY (2) CY1121391T1 (en)
DK (2) DK2997011T3 (en)
EA (1) EA037378B1 (en)
EC (1) ECSP15048122A (en)
ES (2) ES2787704T3 (en)
GT (1) GT201500312A (en)
HK (1) HK1218117A1 (en)
HR (2) HRP20181544T1 (en)
HU (2) HUE039997T2 (en)
IL (2) IL260597B (en)
JO (2) JO3603B1 (en)
LT (2) LT2997011T (en)
ME (1) ME03787B (en)
MX (3) MX366722B (en)
NI (1) NI201500161A (en)
PH (2) PH12015502579B1 (en)
PL (2) PL2997011T3 (en)
PT (2) PT3121164T (en)
RS (2) RS58140B1 (en)
SG (4) SG11201509428PA (en)
SI (2) SI2997011T1 (en)
TW (4) TWI733288B (en)
UA (1) UA117246C2 (en)
UY (1) UY35573A (en)
WO (1) WO2014184350A1 (en)
ZA (1) ZA201508443B (en)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402660YA (en) 2011-12-21 2014-10-30 Novira Therapeutics Inc Hepatitis b antiviral agents
KR102122244B1 (en) 2012-08-28 2020-06-15 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 SUlfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
AU2014222641B2 (en) 2013-02-28 2018-03-15 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
MX353412B (en) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b.
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AU2014267235B2 (en) 2013-05-17 2017-10-05 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
BR112015028501B8 (en) 2013-05-17 2023-01-24 Incyte Corp BIPYRAZOLE DERIVATIVE COMPOUNDS, THEIR SALTS, COMPOSITION COMPRISING THE COMPOUND OR THE SALT, METHOD FOR IN VITRO INHIBITION OF A JAK1 ACTIVITY, AND PROCESS FOR PREPARING PHOSPHORIC ACID SALT
CN108047115B (en) 2013-07-25 2021-06-29 爱尔兰詹森科学公司 Glyoxylamide-substituted pyrrole amide derivatives and their use as medicaments for the treatment of hepatitis B
EA034448B1 (en) 2013-10-23 2020-02-10 Янссен Сайенсиз Айрлэнд Юси Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
US11078193B2 (en) * 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
PT3116316T (en) 2014-03-13 2019-09-30 Assembly Biosciences Inc Hepatitis b core protein allosteric modulators
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) * 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
MX2018000916A (en) 2015-07-22 2018-09-05 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors.
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
TW201720802A (en) 2015-09-15 2017-06-16 艾森伯利生物科學公司 Hepatitis B core protein modulators
CN108430971A (en) 2015-09-29 2018-08-21 诺维拉治疗公司 The crystal form of B type hepatitis antivirus agent
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
PL3426245T3 (en) 2016-03-07 2023-05-22 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
AU2017231817B2 (en) * 2016-03-09 2021-02-25 Emory University Elimination of hepatitis B virus with antiviral agents
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
EP3463469B1 (en) 2016-05-27 2023-12-13 Gilead Sciences, Inc. Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans
CN109843296A (en) 2016-06-10 2019-06-04 英安塔制药有限公司 B type hepatitis antivirus medicament
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
ES2826748T3 (en) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivatives of 4,6-diamino-pyrido [3,2-d] pyrimidine as modulators of Toll-like receptors
CN109937201A (en) 2016-09-15 2019-06-25 组装生物科学股份有限公司 Hepatitis B virus regulator
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
CN110114071B (en) 2016-11-07 2023-07-04 爱彼特生物制药公司 Tricyclic compounds containing substituted pyridones and methods of using the same
EA202190306A1 (en) * 2016-11-11 2021-08-17 Новира Терапьютикс, Инк. COMBINATIONS AND METHODS INCLUDING CAPSID ASSEMBLY INHIBITOR
CN108264520B (en) * 2017-01-03 2021-12-07 上海长森药业有限公司 Compound for treating hepatitis B and application thereof
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
CN108341810B (en) * 2017-01-23 2022-01-18 上海长森药业有限公司 Episulfide urea compound and application thereof
CN108341817B (en) * 2017-01-23 2021-11-26 上海长森药业有限公司 Thiourea, urea compound and use thereof
TWI820984B (en) 2017-01-31 2023-11-01 美商基利科學股份有限公司 Crystalline forms of tenofovir alafenamide
EP3582784B1 (en) 2017-02-16 2022-06-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018153326A1 (en) * 2017-02-22 2018-08-30 上海长森药业有限公司 Sulfonyl hydrazine compound and use thereof
EP3589630B1 (en) 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
SG11201908569QA (en) 2017-03-21 2019-10-30 Arbutus Biopharma Corp Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
JOP20180040A1 (en) 2017-04-20 2019-01-30 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
CN110582500B (en) * 2017-05-04 2022-04-05 上海长森药业有限公司 Bicyclic nucleocapsid inhibitors and their use as medicaments for the treatment of hepatitis b
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as rsv inhibitors
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
AU2018365174B2 (en) 2017-11-13 2023-03-30 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
WO2019113175A1 (en) 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
TW201927789A (en) 2017-12-06 2019-07-16 美商因那塔製藥公司 Hepatitis B antiviral agents
JP7098748B2 (en) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. 2'3'cyclic dinucleotide with phosphonate binding that activates the STING adapter protein
CN111566120B (en) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019154343A1 (en) * 2018-02-09 2019-08-15 正大天晴药业集团股份有限公司 Capsid protein assembly inhibitor, and pharmaceutical composition and use thereof
PL3752501T3 (en) 2018-02-13 2023-08-21 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
MA51829A (en) 2018-02-16 2020-12-23 Incyte Corp JAK1 PATH INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS
PL3759109T3 (en) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
TW201945003A (en) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-diaminoquinazoline derivatives and medical uses thereof
CN111867582A (en) * 2018-03-14 2020-10-30 爱尔兰詹森科学公司 Capsid assembly modulator dosing regimen
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
JP7434166B2 (en) 2018-03-30 2024-02-20 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Inhibitors of the assembly of N-heterocyclic five-membered ring-containing capsid proteins, pharmaceutical compositions and uses thereof
MA52219A (en) 2018-03-30 2021-02-17 Incyte Corp TREATMENT OF SUPPURED HIDRADENITIS USING JAK INHIBITORS
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
TWI833744B (en) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-cyclic dinucleotides
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
JP7242702B2 (en) 2018-04-19 2023-03-20 ギリアード サイエンシーズ, インコーポレイテッド PD-1/PD-L1 inhibitor
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
US11459296B2 (en) 2018-05-16 2022-10-04 Infex Therapeutics Limited Antibacterial compounds
KR20230159715A (en) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 inhibitors
TWI826492B (en) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CA3113235A1 (en) 2018-09-21 2020-03-26 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
JP2022508953A (en) 2018-10-22 2022-01-19 アッセンブリー バイオサイエンシズ,インコーポレイテッド A 5-membered heteroarylcarboxamide compound for the treatment of HBV
KR102635333B1 (en) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 PD-1/PD-L1 inhibitors
WO2020087107A1 (en) 2018-10-31 2020-05-07 The University Of Sydney Compositions and methods for treating viral infections
SG11202103839UA (en) 2018-10-31 2021-05-28 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
AU2019373221B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
WO2020106816A1 (en) 2018-11-21 2020-05-28 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
TW202415643A (en) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
EA202092159A1 (en) 2019-01-25 2020-12-15 Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. CONTAINING N-HETEROCYCLIC FIVE-MERCHED RING CAPSID PROTEIN ASSEMBLY INHIBITOR, ITS PHARMACEUTICAL COMPOSITION AND THEIR APPLICATION
CA3127152A1 (en) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CA3129022C (en) 2019-03-07 2023-08-01 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935066A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
CN113557016A (en) 2019-03-13 2021-10-26 爱尔兰詹森科学公司 Capsid assembly regulator solid formulations
US11254664B2 (en) 2019-03-18 2022-02-22 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
TWI751516B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI751517B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
US20200332297A1 (en) 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CA3132170A1 (en) 2019-04-18 2020-10-22 Michael BIERMER Combination therapy for treating hepatitis b virus infection
CA3132554A1 (en) 2019-05-06 2020-11-12 Bart Rudolf Romanie Kesteleyn Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
AU2020282318A1 (en) 2019-05-24 2021-12-02 Assembly Biosciences, Inc. Pharmaceutical compositions for the treatment of HBV
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US20220305116A1 (en) 2019-06-18 2022-09-29 Janssen Sciences lreland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
WO2020255013A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
CA3140707A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
KR20220032568A (en) 2019-06-25 2022-03-15 길리애드 사이언시즈, 인코포레이티드 FLT3L-FC fusion protein and methods of use
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021046286A1 (en) * 2019-09-04 2021-03-11 Taigen Biotechnology Co., Ltd. Hepatitis b antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
BR112022005687A2 (en) 2019-09-30 2022-06-21 Gilead Sciences Inc Vaccines against hbv and methods to treat hbv
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
KR20220101083A (en) 2019-10-04 2022-07-19 이난타 파마슈티칼스, 인코포레이티드 Antiviral Heterocyclic Compounds
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
UY39032A (en) 2020-01-24 2021-07-30 Enanta Pharm Inc HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS
US20230151027A1 (en) * 2020-02-11 2023-05-18 Ospedale San Raffaele S.R.L. Spirocyclic inhibitors of hepatitis b virus
TW202146008A (en) 2020-02-27 2021-12-16 愛爾蘭商健生科學愛爾蘭無限公司 Treatment of hbv
WO2021178612A1 (en) 2020-03-05 2021-09-10 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
AR121620A1 (en) 2020-03-20 2022-06-22 Gilead Sciences Inc 4-C-SUBSTITUTED-2-HALO-2-DEOXIADENOSINE NUCLEOSIDE PRODRUGS AND METHODS OF PREPARATION AND USE THEREOF
WO2021216661A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
US20230295096A1 (en) 2020-04-22 2023-09-21 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
WO2021216660A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
JP2023523241A (en) 2020-04-22 2023-06-02 アッセンブリー バイオサイエンシズ,インコーポレイテッド Five-membered heteroaryl carboxamide compounds for the treatment of HBV
IL298118A (en) 2020-06-02 2023-01-01 Incyte Corp Processes of preparing a jak1 inhibitor
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
BR112023002164A2 (en) 2020-08-07 2023-03-14 Gilead Sciences Inc PHOSPHONAMIDE NUCLEOTIDE ANALOG PRODRUGS AND THEIR PHARMACEUTICAL USE
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
MX2023006542A (en) 2020-12-08 2023-08-25 Incyte Corp Jak1 pathway inhibitors for the treatment of vitiligo.
WO2022206879A1 (en) * 2021-03-31 2022-10-06 苏州晶云药物科技股份有限公司 Crystal forms of sulfamoyl pyrrole amide compounds and preparation methods therefor
KR20240006683A (en) 2021-05-13 2024-01-15 길리애드 사이언시즈, 인코포레이티드 Combination of TLR8 modulating compounds and anti-HBV siRNA therapeutics
KR20240025616A (en) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023069547A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069544A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069545A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023164186A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164183A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164181A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164179A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843662A (en) 1971-12-09 1974-10-22 Pfizer 2-halo-5-(substituted piperidino sulfonyl)benzoic acids
AU1508183A (en) 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
WO1984003281A1 (en) 1983-02-19 1984-08-30 Beecham Group Plc Azabicycloalkyl benzamide and anilide derivatives
JPS62142164A (en) 1985-12-13 1987-06-25 Ishihara Sangyo Kaisha Ltd 4,5-dichloroimidazole based compound and pest controlling agent containing said compound
IN164880B (en) 1986-01-30 1989-06-24 Ishihara Sangyo Kaisha
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
CA1339133C (en) 1987-03-13 1997-07-29 Rikuo Nasu Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB8904174D0 (en) 1989-02-23 1989-04-05 British Bio Technology Compounds
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
GB9023082D0 (en) 1990-10-24 1990-12-05 Schering Agrochemicals Ltd Fungicides
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5308826A (en) 1993-04-22 1994-05-03 Zeneca Limited Herbicidal 4-substituted pyridyl-3-carbinols
GB9405347D0 (en) 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
US5912260A (en) 1994-05-27 1999-06-15 James Black Foundation Limited Gastrin and CCK antagonists
US5795907A (en) 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
US5763618A (en) 1995-05-12 1998-06-09 Konica Corporation Manufacturing method of sulfides
US5723411A (en) 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE19540995A1 (en) 1995-11-03 1997-05-07 Hoechst Ag Substituted sulfonimidamides, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US6025367A (en) 1996-06-25 2000-02-15 Smithkline Beecham Plc Sulfonamide derivatives as 5HT7 receptor antagonists
WO1998023285A1 (en) 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5994396A (en) 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
ATE413386T1 (en) 1998-01-29 2008-11-15 Amgen Inc PPAR-GAMMA MODULATORS
CA2325638A1 (en) 1998-03-26 1999-09-30 Hideki Yamada Amide derivatives and nociceptin antagonists
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
ATE312081T1 (en) 1999-01-15 2005-12-15 Altana Pharma Ag 6-PHENYLPHENANTHRIDINE WITH PDE-IV INHIBITING EFFECT
IL147150A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
ATE382351T1 (en) 1999-08-10 2008-01-15 Univ Oxford LONG CHAIN N-ALKYL COMPOUNDS AND THEIR OXA DERIVATIVES FOR USE AS ANTIVIRAL AGENTS
MX226123B (en) 1999-09-17 2005-02-07 Millennium Pharm Inc BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa.
PE20010628A1 (en) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd CYCLIC AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE
NZ518886A (en) 1999-12-28 2004-02-27 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
AU2882801A (en) 2000-01-28 2001-08-07 Kaken Pharmaceutical Co., Ltd. Azepine derivatives
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
WO2002051410A2 (en) 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
ATE311387T1 (en) 2000-12-27 2005-12-15 Sumitomo Pharma NEW CARBAPENEM COMPOUNDS, DRUGS AND ANTIBACTERIAL AGENTS CONTAINING SAME, AND USES THEREOF
US7015012B2 (en) 2001-02-09 2006-03-21 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
JP4251872B2 (en) 2001-04-19 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 2-Iminoimidazole derivative (2)
KR100713137B1 (en) 2001-06-28 2007-05-02 동화약품공업주식회사 Novel 2,4-difluorobenzamide derivatives
SE0102315D0 (en) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10136043A1 (en) 2001-07-25 2003-02-13 Degussa Process for the production of modified carbon black
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
ES2242890T3 (en) 2001-11-20 2005-11-16 Eli Lilly And Company BETA 3 AGONISTS OF OXINDOL 3-REPLACED.
SE0201635D0 (en) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
EP1512396A4 (en) 2002-06-05 2008-12-31 Inst Med Molecular Design Inc Inhibitors against the activation of ap-1 and nfat
RU2340605C2 (en) 2002-06-27 2008-12-10 Ново Нордиск А/С Arylcarbonyl derivatives as therapeutic agents
MXPA05000130A (en) 2002-06-27 2005-02-17 Novo Nordisk As Aryl carbonyl derivatives as therapeutic agents.
AU2003254177A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
AU2003252738A1 (en) 2002-08-09 2004-02-25 Ajinomoto Co., Inc. Remedy for intestinal diseases and visceral pain
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
CA2497827A1 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
SE0202838D0 (en) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
US7378525B2 (en) 2002-12-23 2008-05-27 Millennium Pharmaceuticals, Inc. CCR8 inhibitors
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
ATE524452T1 (en) 2003-03-27 2011-09-15 Cytokinetics Inc SULFONAMIDES FOR TREATING CONGESTIVE HEART FAILURE, COMPOSITIONS AND USES THEREOF.
JP2006525366A (en) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー Heterocyclic carboxylic acid substituent
WO2004100947A2 (en) 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
ES2308206T3 (en) 2003-05-13 2008-12-01 Schering Corporation N-ARILSULPHONYLPIPERIDINS WITH SOURCES AS GAMMA-SECRETASE INHIBITORS.
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7498050B2 (en) 2003-12-15 2009-03-03 Kraft Foods Global Brands Llc Edible spread composition and packaged product
DE102004009238A1 (en) 2004-02-26 2005-09-08 Merck Patent Gmbh New aryl amide compounds are kinase inhibitors useful for the treatment and/or prophylaxis of e.g. tumors, psoriasis, rheumatoid arthritis, contact dermatitis, inflammations, endometriosis, scar and benign prostatic hyperplasia
US8404747B2 (en) 2004-03-05 2013-03-26 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
US20080113944A1 (en) 2004-05-04 2008-05-15 Novo Nordisk A/S Novel Indole Derivatives
WO2005115374A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for therapeutic use
CN101005838A (en) 2004-06-22 2007-07-25 先灵公司 Cannabinoid receptor ligands
WO2006012642A2 (en) 2004-07-30 2006-02-02 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
DE102004042441A1 (en) 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Amino acid substituted hexahydro-pyrazino (1,2-a) pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
KR20070048798A (en) 2004-08-31 2007-05-09 아스트라제네카 아베 Quinazolinone derivatives and their use as b-raf inhibitors
US7799915B2 (en) 2004-10-13 2010-09-21 Wyeth Llc Anilino-pyrimidine analogs
KR20070072598A (en) 2004-10-19 2007-07-04 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Indole and benzimidazole derivatives
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
US20060122236A1 (en) 2004-12-06 2006-06-08 Wood Michael R Substituted biaryl-carboxylate derivatives
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
UY29300A1 (en) 2004-12-22 2006-07-31 Astrazeneca Ab CHEMICAL COMPOUNDS
FI117653B (en) 2005-02-21 2006-12-29 Eigenor Oy Procedure and arrangement for sensing objects with a radar
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
SI1940786T1 (en) 2005-09-16 2010-11-30 Arrow Therapeutics Ltd Biphenyl derivatives and their use in treating hepatitis c
RU2008128452A (en) * 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Compounds of N- (6-membered aryl) -amides, Pharmaceutical Composition with Antiviral Activity Based on Them, Method for the Treatment or Prevention of Viral Infection by Means and Methods
BRPI0620255A2 (en) 2005-12-21 2011-11-08 Schering Corp use of cholesterol lowering agents and / or h3 receptor antagonist / inverse agonist
WO2007073935A1 (en) 2005-12-29 2007-07-05 Lek Pharmaceuticals D.D. Heterocyclic compounds
EP2019830A4 (en) 2006-05-04 2011-01-19 Inst Hepatitis & Virus Res Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
FR2903985B1 (en) 2006-07-24 2008-09-05 Sanofi Aventis Sa N- (AMINO-HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2904316B1 (en) 2006-07-31 2008-09-05 Sanofi Aventis Sa N- (AMINO-HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
WO2008022171A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
US20100113421A1 (en) 2006-10-06 2010-05-06 Williams Theresa M Non-nucleoside reverse transcriptase inhibitors
CA2671426C (en) 2006-12-13 2015-05-26 Temple University - Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues useful in the treatment of cancer and other proliferative disorders
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
FR2910473B1 (en) 2006-12-26 2009-02-13 Sanofi Aventis Sa N- (AMINO-HETEROARYL) -1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
JP2008179621A (en) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd Nitrogen-containing saturated heterocyclic compound
JP2008184403A (en) 2007-01-29 2008-08-14 Japan Health Science Foundation New hepatitis c virus inhibitor
MY156814A (en) 2007-03-15 2016-03-31 Novartis Ag Organic compounds and their uses
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
MX2009011951A (en) 2007-05-04 2009-12-11 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors.
CL2008001631A1 (en) * 2007-06-06 2009-01-02 Smithkline Beecham Corp Compounds derived from substituted heterocycles, with the presence of a phenoxy group, reverse transcriptase inhibitors; pharmaceutical composition; and use in the treatment of HIV viral infections.
WO2008154819A1 (en) 2007-06-18 2008-12-24 Zhang, Zhongneng Carbethoxy-substituted thiazolyl dihydropyrimidines
WO2009018219A2 (en) 2007-07-28 2009-02-05 University Of Chicago Methods and compositions for modulating rad51 and homologous recombination
EP2182935A1 (en) 2007-08-02 2010-05-12 F. Hoffmann-Roche AG The use of benzamide derivatives for the treatment of cns disorders
CN101429166B (en) 2007-11-07 2013-08-21 上海特化医药科技有限公司 Quinazoline ketone derivant, preparation method and application thereof
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester Method for altering the lifespan of eukaryotic organisms
FR2926556B1 (en) 2008-01-22 2010-02-19 Sanofi Aventis N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2926555B1 (en) 2008-01-22 2010-02-19 Sanofi Aventis BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2926554B1 (en) 2008-01-22 2010-03-12 Sanofi Aventis AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
FR2926553B1 (en) 2008-01-23 2010-02-19 Sanofi Aventis SILANYL SUBSTITUTED INDOLE-2-CARBOXAMIDE AND AZAINDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CU20080028A6 (en) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech CHEMICAL COMPOUNDS OBTAINED IN SILICO FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO ATTENE OR INHIBIT INFECTION BY DENGUE VIRUSES AND OTHER FLAVIVIRUS
WO2009146013A1 (en) 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
EP2280001B1 (en) 2008-04-24 2014-10-15 Msd K.K. Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20090325960A1 (en) 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
EP2317849A4 (en) 2008-06-26 2011-11-02 Inspire Pharmaceuticals Inc Method for treating pulmonary diseases using rho kinase inhibitor compounds
US20090325959A1 (en) 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
WO2010018113A2 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryl aminotetralines
WO2010027996A1 (en) 2008-09-02 2010-03-11 Institute For Hepatitis And Virus Research Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010043592A1 (en) 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
WO2010059658A1 (en) 2008-11-20 2010-05-27 Glaxosmithkline Llc Chemical compounds
WO2010065782A1 (en) 2008-12-04 2010-06-10 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
TW201036614A (en) 2008-12-30 2010-10-16 Arqule Inc Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds
WO2010088000A2 (en) 2009-02-02 2010-08-05 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
WO2010123139A1 (en) 2009-04-24 2010-10-28 持田製薬株式会社 Arylcarboxamide derivative having sulfamoyl group
US8410141B2 (en) 2009-05-19 2013-04-02 Bayer Cropscience Ag Insecticidal arylpyrrolines
TWI671297B (en) 2009-05-27 2019-09-11 Ptc治療公司 Methods for treating cancer and non-neoplastic conditions
JP2012532102A (en) 2009-06-30 2012-12-13 シガ・テクノロジーズ・インコーポレーテッド Treatment and prevention of dengue virus infection
CA2689707A1 (en) * 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
WO2011058766A1 (en) 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
CN102093320B (en) 2009-12-09 2013-08-28 扬子江药业集团上海海尼药业有限公司 Soluble epoxide hydrolase inhibitor
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2011088561A1 (en) 2010-01-20 2011-07-28 University Of Manitoba Anti-viral compounds and compositions
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
JP2013522192A (en) 2010-03-11 2013-06-13 ブリストル−マイヤーズ スクイブ カンパニー Compounds for the treatment of hepatitis C
CN102206172B (en) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 Substituted diaryl compound and preparation method and antiviral application thereof
US20130018039A1 (en) 2010-03-31 2013-01-17 Bodmer Vera Q Imidazolyl-imidazoles as kinase inhibitors
ME02757B (en) 2010-05-07 2018-01-20 Glaxosmithkline Llc Indoles
US8993622B2 (en) 2010-06-11 2015-03-31 Eirium Ab Antiviral compounds
WO2011163593A2 (en) 2010-06-25 2011-12-29 Philadelphia Health & Education Corporation D/B/A Drexel Induction of immune response
AU2011279909A1 (en) 2010-07-19 2013-01-24 Inspire Pharmaceuticals, Inc. Bifunctional rho kinase inhibitor compounds, composition and use
CA2806664A1 (en) 2010-07-26 2012-02-09 Neurotherapeutics Pharma, Inc. Arylsulfonamide derivatives, compositions, and methods of use
CA2803689A1 (en) 2010-07-27 2012-02-02 Inspire Pharmaceuticals, Inc. Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
WO2012047856A2 (en) 2010-10-04 2012-04-12 Institute For Hepatitis And Virus Research Novel inhibitors of secretion of hepatitis b virus antigens
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US8912195B2 (en) 2010-12-02 2014-12-16 Bristol-Myers Squibb Company Alkyl amides as HIV attachment inhibitors
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
GB201103419D0 (en) 2011-02-28 2011-04-13 Univ Aberdeen
RS62254B1 (en) 2011-04-08 2021-09-30 Janssen Sciences Ireland Unlimited Co Pyrimidine derivatives for the treatment of viral infections
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
JP5977347B2 (en) * 2011-07-01 2016-08-24 バルーク エス.ブルームバーグ インスティテュート Sulfamoylbenzamide derivatives as antiviral agents against HBV infection
SG11201402660YA (en) 2011-12-21 2014-10-30 Novira Therapeutics Inc Hepatitis b antiviral agents
CN104302626B (en) 2012-01-06 2016-09-07 爱尔兰詹森科学公司 4,4-dibasic-1,4-dihydro-pyrimidin and the purposes of the medicine as treatment hepatitis B thereof
WO2013130703A2 (en) 2012-02-29 2013-09-06 Institute For Hepatitis And Virus Research Binhibitors of hepatitis b virus convalently closed circular dna formation and their method of use
RU2014142598A (en) 2012-03-31 2016-05-27 Ф. Хоффманн-Ля Рош Аг NEW 4-METHYLDHYDROPYRIMIDINES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP2861611B1 (en) 2012-05-25 2016-07-13 Janssen Sciences Ireland UC Uracyl spirooxetane nucleosides
CA2874828A1 (en) 2012-06-01 2013-12-05 Drexel University Modulation of hepatitis b virus cccdna transcription
JO3300B1 (en) 2012-06-06 2018-09-16 Novartis Ag Compounds and compositions for modulating egfr activity
AR092348A1 (en) 2012-07-11 2015-04-15 Hoffmann La Roche ARIL-SULTAMO DERIVATIVES AS RORc MODULATORS
KR102122244B1 (en) 2012-08-28 2020-06-15 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 SUlfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
JP6285440B2 (en) 2012-08-28 2018-02-28 ヤンセン・サイエンシズ・アイルランド・ユーシー Fused bicyclic sulfamoyl derivatives and their use as medicaments for the treatment of hepatitis B
MA37942B1 (en) 2012-09-10 2020-01-31 Hoffmann La Roche 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
KR101942151B1 (en) 2012-12-27 2019-01-24 드렉셀유니버시티 Novel antiviral agents against hbv infection
CA2901168C (en) 2013-02-28 2020-09-22 Eisai R&D Management Co., Ltd. Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
AU2014222641B2 (en) 2013-02-28 2018-03-15 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX353412B (en) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b.
PE20151951A1 (en) 2013-05-17 2015-12-26 Hoffmann La Roche HETEROARYLDIHYDROPYRIMIDINES LINKED BY 6 BRIDGES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AU2014267235B2 (en) 2013-05-17 2017-10-05 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
UY35590A (en) 2013-05-28 2014-11-28 Astrazeneca Ab NEW COMPOUNDS FOR CANCER TREATMENT
BR112015029258A2 (en) 2013-05-28 2017-07-25 Bayer Cropscience Ag heterocyclic compounds as pest control agents
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
CN108047115B (en) 2013-07-25 2021-06-29 爱尔兰詹森科学公司 Glyoxylamide-substituted pyrrole amide derivatives and their use as medicaments for the treatment of hepatitis B
WO2015055764A1 (en) 2013-10-18 2015-04-23 Syngenta Participations Ag 3-methanimidamid-pyridine derivatives as fungicides
WO2015057945A1 (en) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
EA034448B1 (en) 2013-10-23 2020-02-10 Янссен Сайенсиз Айрлэнд Юси Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015073774A1 (en) 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis b infections
JO3466B1 (en) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co Tetrahydropyridopyrazines modulators of gpr6
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
ES2721001T3 (en) 2014-01-31 2019-07-26 Cognition Therapeutics Inc Isoindoline derivative, and compositions and methods to treat a neurodegenerative disease
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3114128B1 (en) 2014-03-07 2019-01-02 F. Hoffmann-La Roche AG Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PT3116316T (en) 2014-03-13 2019-09-30 Assembly Biosciences Inc Hepatitis b core protein allosteric modulators
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
MY196243A (en) 2014-03-28 2023-03-24 Sunshine Lake Pharma Co Ltd Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
BR112016028000B1 (en) 2014-05-30 2022-05-17 Qilu Pharmaceutical Co., Ltd Loop derivative of dihydropyrimide as an hbv inhibitor
CA2969557A1 (en) 2014-12-02 2016-06-09 Novira Therapeutics, Inc. Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment
CN107531691A (en) 2014-12-30 2018-01-02 诺维拉治疗公司 Treat the derivative and method of hepatitis B infection
MA41338B1 (en) 2015-01-16 2019-07-31 Hoffmann La Roche Pyrazine compounds for the treatment of infectious diseases
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CA2982811A1 (en) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (en) 2015-09-29 2018-08-21 诺维拉治疗公司 The crystal form of B type hepatitis antivirus agent
CN109251212A (en) 2017-07-14 2019-01-22 上海长森药业有限公司 Inner ring sulfide amide-arylamides and its purposes for treating hepatitis B

Also Published As

Publication number Publication date
US20180141905A1 (en) 2018-05-24
IL260597B (en) 2019-03-31
GT201500312A (en) 2018-01-17
TW201908289A (en) 2019-03-01
SG10201607294SA (en) 2016-10-28
ECSP15048122A (en) 2017-02-24
NI201500161A (en) 2016-01-06
HUE039997T2 (en) 2019-02-28
TWI733288B (en) 2021-07-11
TWI651300B (en) 2019-02-21
PT2997011T (en) 2018-11-30
US9884818B2 (en) 2018-02-06
KR102055639B1 (en) 2019-12-13
CA2909348A1 (en) 2014-11-20
RS60285B1 (en) 2020-06-30
JP2020117530A (en) 2020-08-06
EA201592200A1 (en) 2016-03-31
KR101867898B1 (en) 2018-06-15
KR102223535B1 (en) 2021-03-08
ES2699261T3 (en) 2019-02-08
US10457638B2 (en) 2019-10-29
DK2997011T3 (en) 2018-12-17
HK1218117A1 (en) 2017-02-03
AU2014267220B2 (en) 2017-09-28
CA2909348C (en) 2019-01-08
EP3121164A1 (en) 2017-01-25
ZA201508443B (en) 2020-08-26
HRP20181544T1 (en) 2018-11-30
PH12015502579A1 (en) 2016-02-29
US20160115125A1 (en) 2016-04-28
KR20180066279A (en) 2018-06-18
EP3594204A1 (en) 2020-01-15
SG10202002604PA (en) 2020-05-28
UY35573A (en) 2014-11-28
TWI684586B (en) 2020-02-11
SI3121164T1 (en) 2020-06-30
JP2016518434A (en) 2016-06-23
BR112015028461A2 (en) 2017-07-25
CN105452220B (en) 2019-01-25
PH12015502579B1 (en) 2016-02-29
TW202126620A (en) 2021-07-16
KR20210025712A (en) 2021-03-09
NZ713201A (en) 2021-03-26
IL264541B (en) 2019-09-26
DK3121164T3 (en) 2020-05-11
MX2015015770A (en) 2016-03-11
CN105452220A (en) 2016-03-30
TW202017903A (en) 2020-05-16
HRP20200648T1 (en) 2020-07-10
AU2017276170B2 (en) 2019-07-11
EA037378B1 (en) 2021-03-22
US20200039931A1 (en) 2020-02-06
AU2014267220A1 (en) 2015-11-05
LT3121164T (en) 2020-08-10
CY1121391T1 (en) 2020-05-29
JO3583B1 (en) 2020-07-05
CN110003076A (en) 2019-07-12
EP2997011B1 (en) 2018-08-29
PT3121164T (en) 2020-05-12
PL3121164T3 (en) 2020-07-27
WO2014184350A1 (en) 2014-11-20
CY1123298T1 (en) 2021-12-31
KR20160008574A (en) 2016-01-22
JP2018118990A (en) 2018-08-02
CL2015003370A1 (en) 2016-05-27
RS58140B1 (en) 2019-02-28
PL2997011T3 (en) 2019-03-29
AU2017276170A1 (en) 2018-01-18
PH12018501812A1 (en) 2019-11-18
KR20190139328A (en) 2019-12-17
AU2019236657A1 (en) 2019-10-17
AU2021206827A1 (en) 2021-08-12
MX2019008585A (en) 2019-09-19
TW201522305A (en) 2015-06-16
JO3603B1 (en) 2020-07-05
IL264541A (en) 2019-02-28
SG10201607293UA (en) 2016-10-28
AU2019236657B2 (en) 2021-05-20
ME03787B (en) 2021-04-20
SI2997011T1 (en) 2018-11-30
ES2787704T3 (en) 2020-10-16
EP2997011A1 (en) 2016-03-23
MX2020011810A (en) 2021-10-21
EP3121164B1 (en) 2020-02-19
HUE050236T2 (en) 2020-11-30
LT2997011T (en) 2018-10-25
JP6318238B2 (en) 2018-04-25
UA117246C2 (en) 2018-07-10
MX366722B (en) 2019-07-22

Similar Documents

Publication Publication Date Title
IL264541B (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HRP20181863T1 (en) Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HRP20170945T1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
HK1217330A1 (en) N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b n--
HK1221464A1 (en) Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HK1217326A1 (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
AP2015008814A0 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b